Norian Corporation Cupertino, CA Orthopaedic Trauma and Craniofacial Applications
Vice President, Clinical & Regulatory Affairs Start-up Class III orthopaedic medical device company.
Managed U.S. and international staff of 13 members and all regulatory submissions (3-IDEs approved for distal radius,
intertrochanteric hip, and tibial plateau fractures, 1-PMAA [Norian SRS], 510K [Norian CRS]) domestic &
international (Canadian & CE Mark), and European post-marketing surveillance,
Recruited EU clinical investigators, wrote regulatory applications for research approvals in The Netherlands, Sweden,
Germany, etc., commenced studies in distal radius, tibial plateau, calcaneus, intertrochanteric and femoral neck clinical
applications,
U. S. Committee Chairperson company representative for Japanese joint venture partner [Mochida Pharmaceuticals] to
develop US/Japanese clinical strategy and trial initiation to achieve Ministry of Health commercial approval,
Presented to FDA’s ODE reviewers and Deputy Director, regulatory strategy, and study design before multicenter
clinical study commencement of a {323 subjects} prospective, randomized, multicenter US and EU clinical trial.
Develop documents for regulatory submittals, Investigator Brochures for EU studies, & received FDA approval to
commence feasibility and randomized multicenter trials,
Advised President on Humanitarian Device Use while under clinical investigation,
Received Administrative PMAA approval for Class III orthopedic device, with subsequent PMA approval,
Develop and negotiate budgets and contracts, strategize and identify financial data to establish reimbursement or cost-
effectiveness studies, wrote/edit protocols, hire, and direct clinical/regulatory personnel on a worldwide basis. Met
with European regulators in preparation of Medical Device Directives (Economic Community evolving MDD
approval) and medical device registration (CE Mark),
Wrote technical monographs/white papers, draft publications, meet with venture capitalists and present clinical
applications and data to outside agencies. Ongoing communication with Marketing, Finance, Engineering, and R & D
members; report to the CEO and Board of Directors,
Filed and received Premarket Notification clearance for craniofacial applications,
Presented and met with venture capitalists, Board of Directors, potential investigators, potential investors, and attorneys
in preparation for regulatory documents for public offering.
Alameda, CA In Vitro Diagnostics (IVD) for Ovarian & Breast Cancer
Triton Diagnostics, Inc.
1991-1992
Small In Vitro diagnostic company.
Manager, Clinical Research
Responsible for clinical research budgets, initiate Class III multi-center feasibility clinical trials for ovarian and breast
cancer for PMAA approval,
Designed clinical data base for statistical analysis, recruit investigators, negotiate contracts, IRB approvals, protocol
design and the writing of regulatory reports,
Worked with Marketing & Project Managers for multiple projects, Shell Oil's Legal Consultant for contract
negotiation,
Managed and reorganized Human Specimen Bank to increase efficiency while responsible for the management and
collection of clinical specimens within R & D to meet American Association Tissue Banks (AATB) Standards,
Chair the Research Collaboration Committee comprised of Marketing and R & D scientists. Company acquired by
CIBA Corning Diagnostics.
Urosystems, Inc. Sunnyvale, CA
1991 Urological indications-stress incontinence
Start-up company to treat various forms of stress incontinence.
Director, Clinical Affairs
Developed and responsible for research budget, ensure regulatory compliance for PMAA submission, managed clinical
database, identify and categorize subjects to generate monthly reports,
Met with FDA Inspector as part of a strategic team,
Hired, oriented, & organized research staff, audited the clinical department for FDA and facility inspection, conducted
field audits,
Managed seven domestic and seven international clinical sites. Investor funding not available and the technology was
re-acquired by Medical Device Supplier.
San Jose, CA Interventional neuroradiology & peripheral radiology
Target Therapeutics, Inc.
1989-1991
Clinical Research Director & Acting Regulatory Affairs
New interventional radiology & cardiology angioplasty catheter start-up
Confidential Page 2 of 4
Responsible for the development and management of IDE compliant clinical trials for un-operable brain aneurysms &
AVMs,
Medical Device Reporting (MDR/GMP), annual reports, database development, and commercial product evaluations
for regulatory filings,
Interacted with management and FDA in development of Premarket Notification (510K) and IDE(s),
Field trained CRA's to monitor trials according to Good Clinical Practice(s) and perform internal audits,
Collaborated with research engineers on multiple projects during product development to clinical trials or
commercialization,
Developed and revised Standard Operating Procedures (SOP) in collaboration with Quality Assurance. Developed
budgets & contracted with appropriate consultants,
Wrote and submitted international submissions for research and registrations with subsequent approvals.
Danville, CA
Advanced Biosearch Associates
1988-1989 Clinical and Regulatory Affairs Consultant
Private FDA Regulatory Consulting Firm
Director, Clinical Research
Managed up to 7 internal staff in the clinical research department & co-managed client clinical departments,
Generated budgets and client proposals, trained clinical monitors for field audits according to GCP(s),
Project director for multiple contracted client activities for the development & management of various clinical trials,
Wrote protocols, annual reports, and documents for regulatory submissions, drafted a laser Premarket Notification (510
K) with supporting clinical data acquired under an IDE, received subsequent FDA clearance,
Participated in the writing of IDE(s), device reclassification of a transition device for sutures, attended and prepared
experts' presentations for FDA panel meetings.
Collagen Corporation Palo Alto, CA Dermatology & Plastic Surgery, Oral Surgery, & Orthopaedics
1985-1988
Clinical Research Associate (Senior)
Wrote protocols, safety and efficacy PMA sections, and regulatory reports, interacted with IRB(s), opened and
monitored ~20 clinical domestic Canadian sites, reviewed statistical data, identify experts for contractual work and
negotiate contracts, prepared and monitored study budgets,
Company received PMAA approval for Alveoform for alveolar ridge augmentation; company clinical representative
and collaborated with Zimmer on IDE study for Collagraft,
Oriented/educated new clinical monitors, research assistants, and regulatory affairs personnel, wrote SOP(s), wrote
safety section for PMAA Submission,
Attended FDA Panel meeting as clinical resource, drafting & review of product labeling,
Formally train sales personnel, and represented Medical Affairs at sales and medical meetings.
Collagen Corporation Post-Market Surveillance for Class III bovine collagen dermal filler
1984-1985
Safety Medical Monitor
Collected and monitored data for complaint files and adverse reactions Zyderm, analyzed data for FDA reports,
Completed Phase IV monitoring, designed report forms for data entry and computerized reports, oriented new Monitors
and sales personnel to safety profile of commercialized products,
Maintained complaint files for potential product liability action and collaborate with the Director, Quality Control,
Met with FDA Investigators during quarterly complaint file audits, prepared and monitored budget,
Communicated and educated physicians customer end-users and their patients about the immunological response to
bovine collagen implant during telephone interviews and data collection.
Lieutenant Commander (LCDR) US Navy Nurse Corps (Permanently Inactive)
MILITARY STATUS
George Mason University Fairfax, VA 1982-83 Masters of Science Administration 1982-83
EDUCATION
Marymount College of Virginia Arlington, VA Bachelor of Science in Nursing 1980-82
Cum Laude Marymount College of Virginia
HONORS
President's Cup for outstanding performance
Sales and Marketing award for outstanding clinical performance
Confidential Page 3 of 4
PUBLICATIONS
Reactions to Injectable Collagen: Results in Animal Models and Clinical Use. F. De Lustro, S. T. Smith, J. Sundsmo, et al
Plastic and Reconstructive Surgery: April 1987, 79, 581-592.
Evaluation of Collagen/Hydroxylapatite for Augmenting Deficient Alveolar Ridges: A Preliminary Report. D. Mehlisch,
T. Taylor, D. Leibold, R. Hiatt, D. Waite, P. Waite, D. Laskin, S. T. Smith, & M. Koretz J Oral & Maxillofac Surg, 1987, 45,
408-413.
Collagen/Hydroxylapatite for Augmenting Deficient Alveolar Ridges: 12 Month Results. D. Mehlisch, T. Taylor, D.
Leibold, R. Hiatt, D. Waite, P. Waite, D. Laskin, S. T. Smith J Oral & Maxillofac Surg, 1988, 46, 839-843.
A Process for the In Situ Formation of the Mineral Phase of Bone. B. Constantz, I. Ison, M. Fulmer, R. Poser, S. T. Smith,
M. Van Wagoner, J. Ross, S. Goldstein, J. Jupiter, D. Rosenthal Science, 1995, 267, 1796-1799.
Repair of Five Distal Radius Fractures with Investigational Cancellous Bone Cement: A Preliminary Report. J. Jupiter,
S. Winters, S. Sigman, C. Lowe, C. Pappas, A. Ladd, M. Van Wagoner, S. T. Smith. Journal of Orthopaedic Trauma, 1997,
2,110-116.
Bioactive Materials in Orthopaedic Surgery-Overview and Regulatory Considerations. Bauer, T & S. T. Smith,
Current Orthopaedics and Related Research, Vol. 395, pp 11-22, February 2002.
PRESENTATIONS/Guest Speaker
Guest speaker: Northern California Pharmaceutical Discussion Group
Sales and Marketing for new product introductions and regulatory oversight
FDA & Sponsor Meetings for Pre-IDE and PMA preparations
Women in Science Palo Alto, CA
CONTINUING EDUCATION
Good Clinical Practices 4/14-16/86, Preparing Clinical Protocols & Managing Clinical Investigations 3/88 Regulatory
Compliance GMP/QA/QC/SOP 11/14-18/88, Process Validation 10/89 Good Manufacturing Practices (GMPs) 4/90; FDA
Medical Workshops GMP/Sterile Devices 6/13-14/90; FDA Workshop In Vitro Diagnostic Devices 6/21/90; Drugs & Devices
1991: Current Regulatory Issues 11/7-8/91; Registration of Medical Devices in Europe 7/20-22/92 Good Manufacturing
Practices/Preproduction Quality Assurance 11/13/92, Regulation & Reimbursement of Medical Devices 6/15/93; Designing
Clinical Trials for Approval & Reimbursement 4/18-19/94; European Registration System for Medical Implants (Holland) 6/2-
3/94, Reimbursement Planning & Technology Assessment for Devices 12/5-7/94 Current Good Manufacturing Practice (QSR)
for Medical Devices 3/5-7/01; Combination Products 3/25-26/04, RAPS 2004 Western Symposium (International Regulatory
and new standards), Technology Transfer for Emerging Technologies 5/29-31/07, Medical Device Congress 4/26-28/08,
American Orthopaedic Association of Sports Medicine July 10-13, 2008, RAPS Horizons 3/30-4/3/09, Florida Manufacturer’s
Medical Device 4/7-8/09, & RAPS Annual Meeting 9/13-16/09, FDA Clinical Trial Requirements Regulations, Compliance
and Good Clinical Practices (GCP) 11/4/5/2010, Risk Management for Medical Devices: Applying 14971 Effectively Using
Risk Assessment and Reliability Tools, Advanced Process Validation 3/16-17/2011, & Advanced Site Management: Finance &
Productivity 3/24-25/2011.
PROFESSIONAL ORGANIZATIONS
Regulatory Affairs Professional Society (RAPS),
Society for Clinical Trials,
Society of Clinical Research Associates (SoCRA)
Confidential Page 4 of 4